Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis
Cihan Yurdaydìn, Onur Keskın, Esra Yurdcu, et al.
Hepatology (2021) Vol. 75, Iss. 6, pp. 1551-1565
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

EASL Clinical Practice Guidelines on hepatitis delta virus
Maurizia Rossana Brunetto, G. Ricco, Francesco Negro, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 433-460
Open Access | Times Cited: 129
Hepatitis B Virus-Associated Hepatocellular Carcinoma
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxı̀
Viruses (2022) Vol. 14, Iss. 5, pp. 986-986
Open Access | Times Cited: 113
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 81
Hepatitis D Virus Infection
Tarik Asselah, Mario Rizzetto
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 58-70
Closed Access | Times Cited: 51
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
Mathias Jachs, Caroline Schwarz, Marlene Panzer, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 1, pp. 144-154
Open Access | Times Cited: 59
Interferon‐based treatment of chronic hepatitis D
Lisa Sandmann, Heiner Wedemeyer
Liver International (2022) Vol. 43, Iss. S1, pp. 69-79
Open Access | Times Cited: 43
Hepatitis D
Francesco Negro, Anna S. Lok
JAMA (2023) Vol. 330, Iss. 24, pp. 2376-2376
Closed Access | Times Cited: 40
Diagnosis and Management of Hepatitis Delta Virus Infection
Calvin Pan, Robert G. Gish, Ira M. Jacobson, et al.
Digestive Diseases and Sciences (2023) Vol. 68, Iss. 8, pp. 3237-3248
Open Access | Times Cited: 20
HDV RNA assays: Performance characteristics, clinical utility, and challenges
Heiner Wedemeyer, Mitchell Leus, Thomas R. Battersby, et al.
Hepatology (2023)
Open Access | Times Cited: 18
Hepatitis delta testing trends in a US national cohort: An analysis of patient and provider-level predictive factors
Binu V. John, Mahmoud Manouchehri Amoli, Donna M. Evon, et al.
Hepatology Communications (2024) Vol. 8, Iss. 5
Open Access | Times Cited: 6
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
Vincent Soriano, Víctor Moreno‐Torres, Ana Treviño, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 155-166
Open Access | Times Cited: 14
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
Pietro Lampertico, Elisabetta Degasperi, Lisa Sandmann, et al.
JHEP Reports (2023) Vol. 5, Iss. 9, pp. 100818-100818
Open Access | Times Cited: 14
Prospects for Controlling Hepatitis B Globally
Vincent Soriano, Víctor Moreno‐Torres, Ana Treviño, et al.
Pathogens (2024) Vol. 13, Iss. 4, pp. 291-291
Open Access | Times Cited: 5
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 5
Current and future therapeutic options for chronic hepatitis D virus infection
Mariantonietta Pisaturo, Giovanna Russo, Pierantonio Grimaldi, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 14
Open Access
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
Yi‐Wen Huang, Albert Qin, Chan‐Yen Tsai, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1128-1128
Open Access | Times Cited: 19
Hepatitis Delta Infection: A Clinical Review
Brian L. Pearlman
Seminars in Liver Disease (2023) Vol. 43, Iss. 03, pp. 293-304
Open Access | Times Cited: 11
A bibliometric analysis of the hepatitis D virus and its therapeutic options
Taslima Nasrin, Mehboob Hoque, Safdar Ali
Discover Viruses. (2025) Vol. 2, Iss. 1
Open Access
Targeting NTCP for liver disease treatment: A promising strategy
X H Tan, Xiang Yu, Jianyou Shi, et al.
Journal of Pharmaceutical Analysis (2024) Vol. 14, Iss. 9, pp. 100979-100979
Open Access | Times Cited: 3
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Takeshi Chida, Yuji Ishida, Sho Morioka, et al.
JCI Insight (2023) Vol. 8, Iss. 9
Open Access | Times Cited: 8
Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options
María Buti, Alexia Gonzalez, Mar Riveiro‐Barciela, et al.
United European Gastroenterology Journal (2023) Vol. 12, Iss. 2, pp. 210-218
Open Access | Times Cited: 7
The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies
Adam Khattak, Tahne Vongsavath, Lubaba Haque, et al.
Journal of Clinical and Experimental Hepatology (2024) Vol. 14, Iss. 5, pp. 101395-101395
Closed Access | Times Cited: 2
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
Pietro Lampertico, Maria Paola Anolli, Dominique Roulot, et al.
Gut (2024), pp. gutjnl-332597
Closed Access | Times Cited: 2
Combination of Novel Therapies for HDV
Menashe Elazar, Jeffrey S. Glenn
Viruses (2022) Vol. 14, Iss. 2, pp. 268-268
Open Access | Times Cited: 10
Recent treatment advances and practical management of hepatitis D virus
Kathryn Olsen, Sara Mahgoub, Sarah Al-Shakhshir, et al.
Clinical Medicine (2023) Vol. 23, Iss. 4, pp. 403-408
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top